

PERSONAL INFORMATION **Federico Gulluni, PhD**

📍 Molecular Biotechnology Center (MBC) "Guido Tarone"
Dep. of Molecular Biotechnology and Health Sciences
Via Nizza 52,
10126 Torino, IT

✉ federico.gulluni@unito.it
https://www.dbmss.unito.it/do/docenti.pl/Show?_id=fgulluni

WORK EXPERIENCE

- 2022 – present **(RTDb) Assistant professor**
University of Torino, Dep. of Molecular Biotechnology and Health Sciences
• Laboratory of Phosphoinositide Kinase and Control of Cell Division
Basic and applied research
- 2021-2022 **(RTDa) Junior lecturer**
University of Torino, Dep. of Molecular Biotechnology and Health Sciences
• Laboratory of Phosphoinositide Kinase and Control of Cell Division
Basic and applied research
- 2017 - 2021 **Postdoctoral fellow**
University of Torino
• Postdoctoral Scientist, Control of Cell Division in Brest Cancer
Basic and applied research

EDUCATION AND TRAINING

- 2013 - 2017 **Ph.D. (Doctor of Philosophy)**
University of Torino (Torino, Italy)
• Molecular Medicine
- 2010 - 2012 **M.Sci. (Master of Science)**
University of Torino (Torino, Italy)
• Molecular Biotechnology
- 2007 - 2010 **B.Sci. (Bachelor of Science)**
University of Torino (Torino, Italy)
• Biotechnology

WORK ACTIVITIES

- Teaching activity**
- 2022 – Present SCIENZE BIOMEDICHE 2 (MED3220)
Corso di Laurea in Dietistica, Università di Torino
 - 2022 – Present Struttura e morfologia del corpo umano - D.M. 270/04 (MED3033)
Corso di Laurea in Infermieristica – ASL-TO, Università di Torino
 - 2022 – 2023 Basi biologiche, molecolari e di genetica umana (canale D) (SME0881)
Laurea Magistrale in Medicina e Chirurgia - sede di Torino
- Awards**
- 2022 “Guido Tarone – Under 35 award”, AIBG, IT
 - 2019 – 2021 Pezcoller Foundation – SIC, Two-year postdoctoral fellowship, IT

2019 "Giovanni Angelo Costa" Award for scientific publications. University of Torino, IT
2018 Capturing Cancer Photography Competition, Oncology Central, UK
2018 Early Career Member Bursary Award, Biochemical Society, London UK
2017 Keystone Symposia Future of Science Fund – Scholarship Award, US
2017 – 2019 Three-years AIRC/FIRC fellowship for Italy, IT
2014 Medal for Best Thesis Work (2012), University of Torino, IT
2013 Optime Prize for Master Dissertation, Unione Industriale Torino, IT
2009 – 2013 Mario Negri Foundation study grant, Mario Negri Foundation, Milan IT

Editorial activity 2022 – present Reviewer Editor for Frontiers in Molecular and Cell biology
2021 Guest Editor – Frontiers in Cell and Developmental Biology, Special Issue
“Phosphoinositides and Signal Transduction in Health and Disease”
2020 – present Reviewer activity for Frontiers in Oncology, Frontiers in Molecular and Cell
biology, Frontiers in Pharmacology, Biology, Molecules, Genes, International Journal of
Personalized medicine, International Journal of Medical Science, Journal of Chemotherapy
2020 Topic Editor for Biology (MDPI Journal)

Invited presentations 2022 - ASBMB Lipid Research Division virtual seminar, US

Grants 2023 – 2027 MFAG. Targeting aneuploidy for breast cancer therapeutics.
2020 – 2021 PEZCOLLER FOUNDATION-SIC. Defining The Role of PI3K-C2 α as a New Prognostic
Marker in Breast Cancer Progression.
2017 – 2019 AIRC/FIRC FELLOWSHIP FOR ITALY 19421. Study of the role of PtdIns(3,4)P2 and
PI3K-C2 α in breast cancer.

ADDITIONAL INFORMATION

Publications Number of publications: **21**
Cumulative Impact Factor: **406.6**
Cumulative citation index: **1729** (Scopus);
H-index: **13** (Scopus);

1. De Santis MC, Gozzelino L, Margaria JP, Costamagna A, Ratto E, **Gulluni F**, Di Gregorio E, Mina E, Lorito N, Bacci M, Lattanzio R, Sala G, Cappello P, Novelli F, Giovannetti E, Vicentini C, Andreani S, Delfino P, Corbo V, Scarpa A, Porporato PE, Morandi A, Hirsch E, Martini M. (2023). Lysosomal lipid switch sensitises to nutrient deprivation and mTOR targeting in pancreatic cancer. **GUT** (IF: 31.795)
2. Lo WT, Zhang Y, Vadas O, Roske Y, **Gulluni F**, De Santis MC, Zagar AV, Stephanowitz H, Hirsch E, Liu F, Daumke O, Kudryashev M, Haucke V. (2022). Structural basis of phosphatidylinositol 3-kinase C2 α function. **NATURE STRUCTURAL AND MOLECULAR BIOLOGY** (IF: 18.361)
3. Li H, Prever L, Hsu MY, Lo WT, Margaria JP, De Santis MC, Zanini C, Forni M, Novelli F, Pece S, Di Fiore PP, Porporato PE, Martini M, Belabed H, Nazare M, Haucke V, **Gulluni F** #, Hirsch E #. (2022). Phosphoinositide Conversion Inactivates R-RAS and Drives Metastases in Breast Cancer. **ADVANCED SCIENCE** (IF: 17.521)
4. **Gulluni F**, Prever L, Li H, Krafcikova P, Corrado I, Lo WT, Margaria JP, Chen A, De Santis MC, Cnudde SJ, Fogerty J, Yuan A, Massarotti A, Sarjalo NT, Vadas O, Williams RL, Thelen M, Powell DR, Schueler M, Wiesener MS, Balla T, Baris HN, Tiosano D, McDermott BM Jr, Perkins BD, Ghigo A, Martini M, Haucke V, Boura E, Merlo GR, Buchner DA, Hirsch E. (2021) PI(3,4)P2-mediated cytokinetic abscission prevents early senescence and cataract formation. **SCIENCE** (IF: 63,832).
5. Li H*, Prever L*, Hirsch E, **Gulluni F**. (2021). Targeting PI3K/AKT/mTOR signaling pathway in breast cancer. **CANCERS** (IF: 6,675)
6. Gozzelino L*, De Santis MC*, **Gulluni F***, Hirsch E, Martini M. (2020). PI(3,4)P2 signaling in cancer and metabolism. **FRONTIERS IN ONCOLOGY** (IF: 5.738)
7. Hirsch E, **Gulluni F** and Martini M (2020). Phosphoinositides in cell proliferation and metabolism. **ADVANCES IN BIOLOGICAL REGULATION** (IF: ND)
8. Cisse O, Quraishi M, **Gulluni F**, et al (2019). Downregulation of class II phosphoinositide 3-kinase PI3K-C2P delays cell division and potentiates the effect of docetaxel on cancer cell growth. **J EXP CLIN CANCER RES** (IF: 12,658)
9. Tiosano D*, Baris HN*, Chen A*, Hitzert MM*, Schueler M*, **Gulluni F***, et al (2019). Mutations in PIK3C2A cause syndromic short stature, skeletal abnormalities, and cataracts associated with ciliary dysfunction. **PLOS GENETICS** (IF: 6.020)
10. **Gulluni F**, De Santis MC, Margaria JP, Martini M, Hirsch E. (2019). Class II PI3K Functions in Cell Biology and Disease. **TRENDS IN CELL BIOLOGY** (IF: 21.167)
11. De Santis MC, **Gulluni F**, Campa CC, Martini M, Hirsch E (2019). Targeting PI3K signaling in cancer: Challenges and advances. **BIOCHIM BIOPHYS ACTA REV CANCER** (IF: 11,414)

12. Wang H, Lo WT, Vujicic Zagar A, **Gulluni F**, Lehmann M, Scapozza L, Haucke V, Vadas O. (2018). Autoregulation of Class II Alpha PI3K Activity by Its Lipid-Binding PX-C2 Domain Module. **MOLECULAR CELL** (IF: 19.328).
13. **Gulluni F** et al, (2017). Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2a scaffolding function. **CANCER CELL** (IF: 38.585)
14. **Gulluni F** et al, (2017). Cytokinetic abscission: Phosphoinositides and ESCRTs direct the final cut. **JOURNAL OF CELLULAR BIOCHEMISTRY** (IF: 4.481)
15. Franco I, Margaria JP, De Santis MC, Ranghino A, Monteyne D, Chiaravalli M, Pema M, Campa CC, Ratto E, **Gulluni F**, Perez-Morga D, Somlo S, Merlo GR, Boletta A, Hirsch E (2016). Phosphoinositide 3-Kinase-C2a Regulates Polycystin-2 Ciliary Entry and Protects against Kidney Cyst Formation. **J AM SOC NEPHROL** (IF: 14.981)
16. Li Chew C, Lunardi A**, **Gulluni F****, et al, (2016). In Vivo Role of INPP4B in Tumor and Metastasis Suppression through Regulation of PI3K-AKT Signaling at Endosomes. **CANCER DISCOVERY**. (IF: 38.272)
17. Ciralo E*, **Gulluni F***, Hirsch E (2014). Methods to Measure the Enzymatic Activity of PI3Ks. **METHODS IN ENZYMOLOGY** (IF: 1.682)
18. Martini M, De Santis MC, Braccini L, **Gulluni F**, Hirsch E (2014). PI3K/AKT signaling pathway and cancer: an updated review. **ANNALS OF MEDICINE** (IF: 5.348)
19. Franco I*, **Gulluni F***, et al (2014). PI3K class II a controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. **DEVELOPMENTAL CELL** (IF: 13.417)
20. Posor Y, Eichhorn-Gruenig M**, Puchkov D**, Schoneberg J**, Ullrich A**, Lampe A, Muller R, Zerbakhsh S, **Gulluni F**, Hirsch E, Krauss M, Schultz C, Schmoranzner J, Noé F, Haucke V. (2013). Spatiotemporal Control of Endocytosis by Phosphatidylinositol 3,4-Bisphosphate. **NATURE** (IF: 69.504)
21. Martini M*, Ciralo E*, **Gulluni F***, Hirsch E. (2013). Targeting PI3K in cancer: any good news? **FRONTIERS IN ONCOLOGY** (IF: 5.738)

*Co-first authorship; ** Co-second authorship; # Co-last authorship JCR 2021

Cover picture: TRENDS IN CELL BIOLOGY, Apr 01, 2019. [https://www.cell.com/trends/cell-biology/issue?pii=S0962-8924\(18\)X0005-1](https://www.cell.com/trends/cell-biology/issue?pii=S0962-8924(18)X0005-1)